1361 HBM1022: an afucosylated anti-CCR8 antibody, depletes specifically tumor infiltrating Tregs and inhibits tumor growth with excellent safety profile in preclinical studies

免疫疗法 癌症研究 抗体 肿瘤微环境 免疫学 趋化因子受体 趋化因子 医学 免疫系统
作者
Shuang Lü,Yiping Rong,Xin Gan,Joe Zhao
标识
DOI:10.1136/jitc-2022-sitc2022.1361
摘要

Background

Tumor-infiltrating lymphocyte-Treg cells (TIL-Tregs) contribute to establishment of an immunosuppressive tumor microenvironment (TME). Several immunotherapies, such as anti-CD25 antibodies, are designed to target this type of cells. However, the possibility of undesirable targeting Treg cells in peripheral blood hampers their clinical benefits. CCR8 is a chemokine receptor selectively upregulated on TIL-Tregs from cancers such as clear cell renal cell carcinoma (ccRCC), breast, and bladder cancers, but rarely on Tregs in peripheral blood. This tumor specific expression of CCR8 provides us with an opportunity to develop an immunotherapy targeting TIL-Tregs selectively.

Methods

Results

Conclusions

HBM1022 is a novel Fc-optimized CCR8 antibody with a high affinity to both human and cynomolgus monkey CCR8. It acts through dual mechanisms of action (MOA). HBM1022 recognizes patient-derived TIL-Tregs, and potently depletes CCR8+Treg cells via enhanced antibody-dependent cellular cytotoxicity (eADCC) activity. Furthermore, it inhibits CCL1-CCR8 signaling pathway and blocks CCL1 induced cell migration. HBM1022 exhibits a potent antitumor activity as monotherapy and in combination with anti-PD (L)1 antibodies. HBM1022 has favorable pharmacokinetic properties and an excellent safety profile in cynomolgus monkey, which suggests a potential good safety profile in human.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
今后应助柠檬味电子对儿采纳,获得10
刚刚
思源应助大黑狗采纳,获得10
1秒前
1秒前
科研通AI2S应助松果采纳,获得10
2秒前
2秒前
3秒前
科研小能手完成签到,获得积分10
4秒前
cctv18应助加油写论文采纳,获得30
4秒前
怀海的鱼完成签到,获得积分10
5秒前
6秒前
小其发布了新的文献求助10
6秒前
6秒前
sp完成签到,获得积分10
7秒前
Henry应助Foura采纳,获得200
7秒前
呆萌语梦完成签到,获得积分10
7秒前
7秒前
阿朱发布了新的文献求助10
7秒前
8秒前
NexusExplorer应助Veronica采纳,获得10
9秒前
后来驳回了Owen应助
11秒前
无花果应助Peanut采纳,获得10
11秒前
11秒前
1021完成签到 ,获得积分10
11秒前
白白熊发布了新的文献求助10
12秒前
蔡晓华发布了新的文献求助10
12秒前
12秒前
13秒前
14秒前
zc19891130完成签到,获得积分10
16秒前
研友_VZG7GZ应助松果采纳,获得10
16秒前
20秒前
21秒前
Peanut发布了新的文献求助10
25秒前
美满的皮卡丘完成签到 ,获得积分10
27秒前
王w完成签到,获得积分10
29秒前
29秒前
罗盘完成签到,获得积分10
29秒前
甜美幻露应助松果采纳,获得10
29秒前
鹿飞完成签到,获得积分10
30秒前
31秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Very-high-order BVD Schemes Using β-variable THINC Method 830
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3247691
求助须知:如何正确求助?哪些是违规求助? 2890959
关于积分的说明 8265537
捐赠科研通 2559214
什么是DOI,文献DOI怎么找? 1387979
科研通“疑难数据库(出版商)”最低求助积分说明 650670
邀请新用户注册赠送积分活动 627552